Bemiparin versus unfractionated heparin as bridging therapy in the perioperative management of patients on vitamin K antagonists: The BERTA study

Clinical Drug Investigation

Volumn 33, Issue 12, 2013, Pages 921-928

  Santamaría, Amparo ^a   Ugarriza, Arantxa ^b   Muñoz, Carmen ^c   De Diego, Isabel ^d   López Chulia, Francisca ^e   Benet, Carmen ^e   Martínez González, Javier ^f   Gómez, Natividad ^g   Pina, Elena ^h   Ortín, Xavier ⁱ   Marco, Pascual ^j   Roncalés, Franciso Javier ^k   Fontcuberta, Jordi ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^d Hospital Universitari Mutua Terrassa   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f Laboratorios Farmaceuticos Rovi SA   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ HOSPITAL VERGE DE LA CINTA   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; BEMIPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADOLESCENT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; INVASIVE PROCEDURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PERIOPERATIVE CARE; TREATMENT OUTCOME; VITAMIN K;

EID: 84890308838     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0141-6     Document Type: Article

References (30)

1. Vinik R, Wanner N, Pendleton RC. Periprocedural antithrombotic management: a review of the literature and practical approach for the hospitalist physician. J Hosp Med. 2009;4:551-9.
2. Constans M, Santamaría A, Mateo J, et al. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract. 2007;61:212-7.
3. Boriani G, Biffi M, Diemberger I, et al. Perioperative managment of patients taking antithrombotic therapy: need for an integrated proactive approach. Int J Clin Pract. 2011;65:231-44.
4. Kaatz S, Paje D. Update in bridging anticoagulation. J Thromb Thrombolysis. 2011;31:259-64.
5. Spyropoulos AC. Bridging therapy and oral anticoagulation: current and future prospects. Curr Opin Hematol. 2010;17:444-9.
6. Palaniswamy C, Selvaraj DR. Periprocedural bridging anticoagulation: current perspectives. Am J Ther. 2011;18:e89-94.
7. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e326S-50S.
8. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163:901-8.
9. Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med. 2003;163:881-3.
10. The BRIDGE Study Investigators. Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure? Circulation. 2012;125:e496-8.
11. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the PROSpective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5:2211-8.
12. Klamroth R, Gottstein S, Essers E, et al. Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy. Vasa. 2010;39:243-8.
13. Hammerstingl C, Schmitz A, Fimmers R, et al. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. Cardiovasc Ther. 2009;27:230-8.
14. Dunn A. Perioperativemanagement of oral anticoagulation: when and how to bridge. J Thromb Thrombolysis. 2006;21:85-9.
15. Spyropoulos AC, Turpie AG, Dunn AS, et al. REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006;4:1246-52.
16. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319-26.
17. Spyropoulos AC, Turpie AG, Dunn AS, et al. REGIMEN Investigators. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN registry). Am J Cardiol. 2008;102:883-9.
18. Martínez-González J, Rodríguez C. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin. Expert Rev Cardiovasc Ther. 2010;8:625-34.
19. Planès A. Review on bemiparin sodium - a new second generation low-molecular-weight heparin - and its applications in venous thromboembolism. Expert Opin Pharmacother. 2003;4:1551-61.
20. Westmuckett AD, Kakkar VV, Hamuro T, et al. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro. Thromb Haemost. 2001;86:1547-54.
21. Moreno González E, Fontcuberta J, de la Llama F, EMRO (Grupo Estudio Multicéntrico RO-11). Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepato-Gastroenterology. 1996;43:744-7.
22. Kakkar VV, Howes J, Sharma V, et al. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment Group. Thromb Haemost. 2000;83:523-9.
23. Santamaría A, Juárez S, Reche A, The ESFERA Investigators, et al. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study. Int J Clin Pract. 2006;60:518-25.
24. De Lorenzo F, Newberry D, Scully M, et al. Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure. Am Heart J. 2002;143:689-95.
25. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Ann Int Med. 2010;152:726-32.
26. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110:1658-63.
27. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost. 2010;8:107-13.
28. Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116:2531-4.
29. Halbritter KM, Wawer A, Beyer J, et al. Bridging anticoagulation for patients on long-term vitamin-K-antagonists: a prospective 1 year registry of 311 episodes. J Thromb Haemost. 2005;3:2823-5.
30. Dentali F, Riva N, Malato A, et al. Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. J Thorac Cardiovasc Surg. 2009;137:91-3.